Total amount raised
$207 Million
Latest funding date
01/01/2025
Location
Atalanta Therapeutics has successfully raised funding over two rounds, with the latest being a Series B round. The company is backed by nine investors, including RiverVest, GHR Foundation, EQT Life Sciences, and Sanofi Ventures.
Keep reading to explore the intricacies of Atalanta Therapeutics' fundraising journey and the investors backing this innovative biotechnology company.
What Is Atalanta Therapeutics?
Atalanta Therapeutics is a biotechnology company based in Boston, Massachusetts, dedicated to pioneering new treatment options for neurodegenerative diseases. The company leverages RNA interference (RNAi) technology to develop therapeutic approaches aimed at halting neurological diseases at their source.
Founded with a mission to address central nervous system (CNS) diseases, Atalanta Therapeutics has grown to employ between 51 and 100 people. The company has successfully raised funding through Series B rounds and is backed by multiple investors, including RiverVest and GHR Foundation.
How Much Funding Has Atalanta Therapeutics Raised?
- Series A
- Amount Raised: USD 110,000,000
- Date: January 2021
- Lead Investors: F-Prime
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To accelerate the development of RNAi-based therapies for neurodegenerative diseases.
- Series B
- Amount Raised: USD 97,000,000
- Date: January 2025
- Lead Investors: EQT Life Sciences, Sanofi Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand clinical trials and advance the pipeline of RNAi therapeutics.
Total Amount Raised: USD 207,000,000. Current Valuation: Not publicly disclosed.
Key Investors
- EQT Life Sciences
- Details: EQT Life Sciences is a prominent investor in the biotechnology sector, known for backing innovative healthcare companies. They were a lead investor in Atalanta Therapeutics' Series B funding round.
- Investment Focus Areas: Biotechnology, Healthcare, Life Sciences
- Notable Investments: Atalanta Therapeutics
- Sanofi Ventures
- Details: Sanofi Ventures is the venture capital arm of Sanofi, a global healthcare leader. They focus on early-stage investments in innovative life sciences companies.
- Investment Focus Areas: Biotechnology, Pharmaceuticals, Digital Health
- Notable Investments: Atalanta Therapeutics
- F-Prime
- Details: F-Prime is a global venture capital firm with a focus on healthcare and technology. They were the lead investor in Atalanta Therapeutics' Series A funding round.
- Investment Focus Areas: Healthcare, Biotechnology, Technology
- Notable Investments: Atalanta Therapeutics
What's Next for Atalanta Therapeutics?
Unfortunately, the provided sources do not contain any specific information about the opportunities available for Atalanta Therapeutics, the size and potential of these opportunities, future fundraising opportunities, industry trends, challenges the company might face, or predictions for future fundraising or acquisitions. Therefore, I am unable to fulfill the user prompt as requested.
The sources provided are either security verification pages or placeholder pages meant for documentation examples, and they do not contain any relevant information about Atalanta Therapeutics or the biotechnology industry.
Use Clay to Get Funding Data
Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like Atalanta Therapeutics and gather other critical business insights.
Sign up for free to start exploring the wealth of information available at your fingertips.
